ArticleTrials2026
Suprapapillary stent-by-stent deployment using slim fully covered metal stents versus plastic stents for unresectable malignant hilar biliary obstruction (SBSFLUX Trial): protocol for a multicenter randomized controlled trial.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiliary drainage is essential for patients with malignant hilar biliary obstruction (MHBO) to relieve obstructive jaundice and cholangitis and improve survival and quality of life. Uncovered metal stents (MS) are recommended for unresectable cases because of their superior duration of patency; however, their removal is technically difficult once an occlusion occurs. Plastic stents (PS) have regained attention owing to being easily removable, particularly as advances in antitumor therapies have led to prolonged survival and increased need for reintervention; however, their patency remains limited. Recently, slim fully covered MS (FCMS) have been reported to reduce the risk of side branch occlusion and may combine long-term patency with removability. This trial aims to evaluate the efficacy and safety of suprapapillary stent-by-stent (SBS) deployment of slim FCMS compared with PS deployment in patients with unresectable MHBO.
methodsThis is a multicenter, randomized, open-label, parallel-group study. Patients with unresectable MHBO classified as Bismuth type II or higher are eligible for inclusion. After informed consent is obtained, the patients will be randomized (1:1) to undergo suprapapillary SBS deployment (placement above the duodenal papilla) with either a slim FCMS or PS. The slim FCMS that will be used in this study have a 6-mm diameter, and both the FCMS and PS are equipped with a distal retrieval string to facilitate stent removal during reintervention. The primary endpoint is the rate of non-recurrent biliary obstruction (RBO) at 6 months following the intervention. Secondary endpoints include the time to RBO, overall survival, procedure success rate, clinical success rate, procedure time, adverse events, and reintervention outcomes. The target sample size is 70 patients (35 patients per group). DISCUSSION: Suprapapillary SBS deployment using slim FCMS may provide longer stent patency while preserving the feasibility of reintervention, potentially establishing a new standard biliary drainage method for unresectable MHBO.
trial registrationJapan Registry of Clinical Trials: jRCT1040250073 registered on August 5, 2025. ( https://jrct.mhlw.go.jp/en-latest-detail/jRCT1040250073 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.